Nitric Oxide-cGMP Signaling in Hypertension : Current and Future Options for Pharmacotherapy
For the treatment of systemic hypertension, pharmacological intervention in nitric oxide-cyclic guanosine monophosphate signaling is a well-explored but unexploited option. In this review, we present the identified drug targets, including oxidases, mitochondria, soluble guanylyl cyclase, phosphodiesterase 1 and 5, and protein kinase G, important compounds that modulate them, and the current status of (pre)clinical development. The mode of action of these compounds is discussed, and based upon this, the clinical opportunities. We conclude that drugs that directly target the enzymes of the nitric oxide-cyclic guanosine monophosphate cascade are currently the most promising compounds, but that none of these compounds is under investigation as a treatment option for systemic hypertension.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Hypertension (Dallas, Tex. : 1979) - 76(2020), 4 vom: 07. Okt., Seite 1055-1068 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ataei Ataabadi, Ehsan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.04.2021 Date Revised 30.04.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1161/HYPERTENSIONAHA.120.15856 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314032959 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314032959 | ||
| 003 | DE-627 | ||
| 005 | 20231225151846.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/HYPERTENSIONAHA.120.15856 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1046.xml |
| 035 | |a (DE-627)NLM314032959 | ||
| 035 | |a (NLM)32829664 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ataei Ataabadi, Ehsan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nitric Oxide-cGMP Signaling in Hypertension |b Current and Future Options for Pharmacotherapy |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.04.2021 | ||
| 500 | |a Date Revised 30.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a For the treatment of systemic hypertension, pharmacological intervention in nitric oxide-cyclic guanosine monophosphate signaling is a well-explored but unexploited option. In this review, we present the identified drug targets, including oxidases, mitochondria, soluble guanylyl cyclase, phosphodiesterase 1 and 5, and protein kinase G, important compounds that modulate them, and the current status of (pre)clinical development. The mode of action of these compounds is discussed, and based upon this, the clinical opportunities. We conclude that drugs that directly target the enzymes of the nitric oxide-cyclic guanosine monophosphate cascade are currently the most promising compounds, but that none of these compounds is under investigation as a treatment option for systemic hypertension | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a mitochondria | |
| 650 | 4 | |a nitric oxide | |
| 650 | 4 | |a oxidoreductase | |
| 650 | 4 | |a soluble guanylyl cyclase | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Nitric Oxide |2 NLM | |
| 650 | 7 | |a 31C4KY9ESH |2 NLM | |
| 650 | 7 | |a Soluble Guanylyl Cyclase |2 NLM | |
| 650 | 7 | |a EC 4.6.1.2 |2 NLM | |
| 650 | 7 | |a Cyclic GMP |2 NLM | |
| 650 | 7 | |a H2D2X058MU |2 NLM | |
| 700 | 1 | |a Golshiri, Keivan |e verfasserin |4 aut | |
| 700 | 1 | |a Jüttner, Annika |e verfasserin |4 aut | |
| 700 | 1 | |a Krenning, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Danser, A H Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Roks, Anton J M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hypertension (Dallas, Tex. : 1979) |d 1983 |g 76(2020), 4 vom: 07. Okt., Seite 1055-1068 |w (DE-627)NLM000456136 |x 1524-4563 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2020 |g number:4 |g day:07 |g month:10 |g pages:1055-1068 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15856 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2020 |e 4 |b 07 |c 10 |h 1055-1068 | ||